World Safety Biomarkers Summit
|Event Date/Time: Dec 03, 2010|
How safety biomarkers can provide a more rational path to drug development.
Translating safety biomarkers from preclinical studies into clinical development.
Addressing the regulatory barriers for safety biomarker qualification.
How drug developers are identifying and validating organ-specific biomarkers.
Improving our understanding of the role of genomic technologies in safety biomarker identification.
Understanding the most appropriate tests to use for safety biomarker identification.
How to enhance collaboration between pharma industry, clinicians and academics to drive forward safety biomarker development.
Why should you attend this meeting?
To learn how to accelerate development of safety biomarkers from pre-clinical studies to the clinic
To discover what regulatory criteria must be satisfied for safety biomarker qualification
To understand how to validate novel safety biomarkers against existing ones
To gain an assembly of new ideas and contacts to take back to your research/regulatory organisations
to download the meeting agenda and for more information!
When registering please remember to quote your priority booking code: ALLCONF